Analyst Price Targets — HUMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 1:26 pm | Ryan Zimmerman | BTIG | $2.00 | $0.64 | StreetInsider | BTIG Reiterates Buy Rating on Humacyte (HUMA) |
| December 1, 2025 11:35 am | Swayampakula Ramakanth | H.C. Wainwright | $3.00 | $1.35 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA) |
| October 13, 2025 11:19 am | — | UBS | $6.00 | $1.68 | TheFly | Humacyte price target lowered to $6 from $7 at BTIG |
| August 27, 2025 8:37 am | Matt Miksic | Barclays | $3.50 | $1.47 | TheFly | Humacyte initiated with an Overweight at Barclays |
| October 18, 2024 7:51 am | Matt O'Brien | Piper Sandler | $6.00 | $4.86 | StreetInsider | Piper Sandler Reiterates Neutral Rating on Humacyte (HUMA) |
| October 18, 2024 5:41 am | Ryan Zimmerman | BTIG | $10.00 | $4.86 | StreetInsider | BTIG Reiterates Buy Rating on Humacyte (HUMA) |
| December 20, 2022 10:49 am | Cowen Cowen | Cowen & Co. | $5.00 | $2.21 | Pulse 2.0 | Humacyte (HUMA) Stock Gets A $5 Price Target |
| May 15, 2022 9:11 pm | Matt O'Brien | Piper Sandler | $4.00 | $5.37 | TheFly | Humacyte downgraded to Underweight from Overweight at Piper Sandler |
Latest News for HUMA
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
NEW YORK and NEW ORLEANS, Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Analyst Recommendations This is a summary of recent recommendations
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for HUMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.